Acumen Pharmaceuticals (ABOS) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Business highlights and clinical progress

• Initiated a global phase 2 study of sabirnetug, targeting full enrollment of 540 patients in the first half of next year.

• Completed a phase 1 study of a subcutaneous version of sabirnetug, with data expected in Q1 2025.

• Sabirnetug is a monoclonal antibody with high selectivity for A beta oligomers, believed to be the primary toxic agent in Alzheimer's disease.

• The asset is wholly owned and has shown promising safety and efficacy signals in early studies.

• Cash position at the end of Q3 was $260 million, with runway into the first half of 2027.

Scientific rationale and differentiation

• Sabirnetug targets low-to-mid molecular weight A beta oligomers, avoiding monomers and potentially reducing off-target effects.

• Designed as an IgG2 antibody with reduced effector function to minimize ARIA risk while maintaining some clearance activity.

• Developed a custom ELISA-based assay to measure drug-oligomer complexes and confirm target engagement.

• Phase 1 data showed competitive plaque reduction and a manageable ARIA rate, with no ARIA-E in E4 homozygotes.

• Dosing for phase 2 (35 and 50 mg/kg) was selected based on target engagement plateau and safety modeling.

Forward-looking statements and industry context

• Subcutaneous phase 1 data expected in Q1 2025; phase 2 enrollment to complete in H1 2025, with data readout roughly 18 months later.

• Subcutaneous strategy will depend on phase 2 IV data and PK results.

• The Alzheimer's antibody landscape is evolving, with next-gen agents and new delivery modalities under development.

• Sabirnetug is positioned as a next-generation A beta antibody, aiming for improved safety and efficacy.

• Strong enrollment in phase 2 reflects high unmet need and team execution.